- €14.09bn
- €14.09bn
- €1.89bn
Brief: Orion Q1 Sales Up At EUR 354.6 Million
Earnings Poll: Orion first quarter results due on April 23
Brief: Orion Concludes Statutory Negotiations In Turku
Brief: Court Of Appeal Fines Orion Board Member
Brief: Orion To Open New Centre In Cambridge, In 2025 To Support Global Growth Strategy, Considers Reorganizing Some Work In Turku
Brief: Orion And Aiforia Extend Collaboration To Preclinical Study Evaluations
Nubeqa strength boosts Orion shares
Orion gains on another outlook hike
Brief: Orion, Marinus Terminate Agreement For Ganaxolone In Europe
Brief: Orion, Abilita Therapeutics Announce Research Collaboration
Brief: Orion Oyj Says Financial Supervisory Authority Has Imposed Penalty Payment Of EUR 6,000 On Ari Lehtoranta, Member Of Board Of Directors Of Orion
Brief: Orion And Alligator Bioscience Amend Their Agreement Concerning Two Bispecific Antibodies
Brief: Orion Keeps 2024 Outlook
Brief: Orion Q3 Operating Profit EUR 202 Million Vs. Estimate EUR 190.5 Million
Orion falls as it ends painkiller development program
Brief: Orion Terminates Odm-111 Development Program Due To Narrow Therapeutic Window Of The Molecule
Brief: Orion's Partner Bayer Submits Application For Third Indication Of Darolutamide In EU
Finland's Orion eyes US sales boost with blockbuster prostate cancer drug
Brief: Bayer Applies To U.S. FDA For Third Darolutamide Indication, Orion's First Blockbuster